RPIDNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
RAPID MICRO BIOSYSTEMS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$0.77+0.01 (+1.20%)
Close on Oct 19, 2026
- Market cap
- $37.40M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Operating margin
-141.1%+48.9 pts over 5 years
Net margin
-140.3%+90.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +19.7% | +25.2% | +15.9% | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 35.4% | -86.8% | |
| Return on assets | – | – | -54.5% | |
| Current ratio | – | 4.00 | 3.31 | |
| Debt to equity | – | -0.20 | 0.57 | |
| Net debt to EBITDA | – | 0.18× | 0.03× | |
| Interest coverage | – | -8.9× | -43.5× | |
| Capex to revenue | – | 4.3% | 2.5% | |
| Diluted shares | – | 0M | 45M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Rapid Micro Biosystems generated $233.81M from operations and spent $14.02M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$233.81M
Used
$14.02M
Capital expenditure$14.02M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-140.3%
×Asset turnover0.39×
×Equity multiplier1.59×
=Return on equity, FY2025-86.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -140.3% | 0.39× | 1.59× | -86.8% |
| FY2024 | -167.2% | 0.23× | 1.25× | -48.5% |
| FY2023 | -233.0% | 0.13× | 1.18× | -37.2% |
| FY2022 | -354.9% | 0.08× | 1.12× | -31.6% |
| FY2021 | -316.5% | 0.15× | 3.31× | -156.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$47.12M
- Cash generatingOperating cash flow above zero-$31.06M
- Return on assets improvedROA up on the prior year-32.7% → -48.0%
- Earnings backed by cashOperating cash flow above net income-$31.06M vs -$47.12M
- Less leverageLong-term debt to assets fell0.0% → 25.3%
- Better liquidityCurrent ratio rose4.61 → 3.31
- No dilutionShare count did not rise44M → 45M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.20 → 0.34